Program
zatolmilast
Also written as “BPN14770”, “BPN14770/ zatolmilast” and “Zatolmilast/ BPN14770”.
Its studies are mostly in Fragile X Syndrome · Alzheimer Disease · Neurodevelopmental Disorders · Renal Insufficiency, led by Shionogi.
Furthest: phase 3, since Dec 15, 202113 company-led studies, 2 open or runningNext primary completion: Sep 30, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shionogi | 132 open or running | phase 3since Dec 15, 2021 | Jan 4, 2016 | Sep 30, 2027phase 3 · NCT05367960 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 4, 2016First study: phase 1 study in Alzheimer DiseaseFirst studyNCT02648672 · 32 enrolled · United States
- Jul 19, 2016Phase 1 study in Alzheimer DiseaseNCT02840279 · 77 enrolled · United States
- Jan 17, 2017Phase 1 study in Alzheimer DiseaseNCT03030105 · 38 enrolled · United States
- May 25, 2018Phase 2 study in Fragile X SyndromeNCT03569631 · 30 enrolled · United States
- Jan 18, 2019Phase 2 study in Alzheimer DiseaseNCT03817684 · 255 enrolled · United States
- Aug 2, 2019Phase 1 study in To Determine Brain Target Occupancy of BPN14770NCT04044781 · United States
- Dec 15, 2021Phase 3 study in Fragile X SyndromeNCT05163808 · 163 enrolled · United States
- Apr 27, 20222 phase 3 studies in Fragile X SyndromeNCT05358886, NCT05367960
- Dec 2, 2024Phase 2 study in Jordan's SyndromeNCT06717438 · 30 enrolled · United States
- Jun 2, 20253 phase 1 studiesNCT07012005, NCT07011992, NCT07018492
Ahead
- Sep 30, 2027Primary completion: phase 3 study in Fragile X SyndromeNCT05367960
- Dec 31, 2027Primary completion: phase 2 study in Jordan's SyndromeNCT06717438
TargetBeta
PDE4D →read by rule
“Phosphodiesterase 4D inhibitor”ChEMBL 37, by rule
Other programs on PDE4D
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Roflumilastrule | AstraZeneca | phase 4 | 61 |
| apremilastrule | Amgen | phase 4 | 48 |
| ensifentrinerule | Merck | phase 3 | 17 |
| difamilastrule | Otsuka | phase 3 | 16 |
| tanimilastrule | Chiesi Farmaceutici | phase 3 | 15 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07018492Hepatic Impairment · United States | 1 | Completed | Nov 26, 2025 | 32 |
| NCT07012005Renal Insufficiency · United States | 1 | Completed | Dec 15, 2025 | 14 |
| NCT07011992Healthy Participants · United States | 1 | Completed | Jul 31, 2025 | 12 |
| NCT06717438Jordan's Syndrome · United States | 2 | Active, not recruiting | Dec 31, 2027 | 30 |
| NCT05367960Fragile X Syndrome · United States | 3 | Active, not recruiting | Sep 30, 2027 | 314 |
| NCT05358886Fragile X Syndrome · United States | 3 | Completed | Jul 18, 2025 | 171 |
| NCT05163808Fragile X Syndrome · United States | 3 | Completed | Sep 2, 2025 | 163 |
| NCT04044781To Determine Brain Target Occupancy of BPN14770 · United States | 1 | Withdrawn | Apr 30, 2020 | 0 |
| NCT03817684Alzheimer Disease · United States | 2 | Completed | Feb 4, 2020 | 255 |
| NCT03569631Fragile X Syndrome · United States | 2 | Completed | Jul 31, 2020 | 30 |
| NCT03030105Alzheimer Disease · United States | 1 | Completed | May 2017 | 38 |
| NCT02840279Alzheimer Disease · United States | 1 | Completed | Nov 2016 | 77 |
| NCT02648672Alzheimer Disease · United States | 1 | Completed | Feb 2016 | 32 |
How it is read
Names in the registry
- “BPN14770”, 9 entries
- “zatolmilast”, 1 entry
- “BPN14770/ zatolmilast”, 1 entry
- “Zatolmilast/ BPN14770”, 1 entry
- “BPN14770, T2310”, 1 entry
Conditions, from the studies’ own filings
- Fragile X Syndrome, 4 studies
- Alzheimer Disease, 4 studies
- Neurodevelopmental Disorders, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.